Gilead’s Kite submits FDA approval application for CAR-T in slow-growing lymphomas

The company said Friday that it had submitted for approval of Yescarta in follicular and marginal zone lymphoma, based on data from the ZUMA-5 study that were presented at the 2020 ASCO meeting in May.